Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Opdiva

- PMLiVE

NICE U-turn sees Opdivo backed as adjuvant therapy for skin cancer

But it is only available via the CDF for now

- PMLiVE

FDA green lights BMS’ multiple myeloma combo

Speedy approval follows a breakthrough designation

- PMLiVE

BMS CEO tackles investor ‘frustrations’ on immuno-oncology

Company faces pressure from competitors in renal cell carcinoma

- PMLiVE

Keytruda hits survival targets in first-line kidney cancer

New data presented at ESMO congress

- PMLiVE

BMS finds a new immunotherapy partner with $12m Compugen deal

Combination with novel antibody targeting PVRIG pathway

Bristol Myers Squibb logo

BMS psoriasis drug hits the mark in phase II

Tyrosine kinase 2 (Tyk2) inhibitors could play major role

- PMLiVE

MSD wins key EU approval for Keytruda, Alimta combo

Decision keeps Keytruda well ahead of rival Tecentriq

- PMLiVE

FDA green lights BMS’ Opdivo for ‘hard-to-treat’ small cell lung cancer

Becomes the first checkpoint inhibitor for this indication

Keytruda’s secret sauce

Merck’s position in oncology is about much more than a good product

- PMLiVE

Keytruda is first I-O drug cleared for melanoma in China

Company chasing rival BMS in world's biggest market

- PMLiVE

Daily Brief: GSK unveils R&D plan, Keytruda OK’d for lymphoma by NICE

News from pharma, biotech and healthcare

- PMLiVE

Daily Brief: Keytruda and microbiome synergy, Pfizer’s files PARP contender and more

Your daily injection of pharma news

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links